Prognostic value and optimal threshold of first thyroglobulin in low/intermediate risk DTC.


Journal

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
ISSN: 1827-1936
Titre abrégé: Q J Nucl Med Mol Imaging
Pays: Italy
ID NLM: 101213861

Informations de publication

Date de publication:
Mar 2021
Historique:
pubmed: 28 3 2019
medline: 21 10 2021
entrez: 28 3 2019
Statut: ppublish

Résumé

The aim of this study was to define prognostic value and optimal threshold of first thyroglobulin (fTg) measured after thyroidectomy and just before radio-iodine therapy (RIT), in low/intermediate risk patients with differentiated thyroid cancer (DTC). This is a retrospective study in 383 patients with DTC who were treated with surgery followed by RIT. Response to treatment was assessed 1 and 2 years after RIT. Odds ratio of different risk factors like age, sex, TNM stage, fTg and Anti-Tg Ab were compared between patients with and without incomplete response 1 and 2 years after treatment. Receiver operating curve analysis was used for definition of optimal fTg cut off for detection of incomplete response. 218 female and 55 male with DTC had negative anti-Tg antibody (mean age: 37.5±14.5 years) and analyzed separately. fTg≥33.5 ng/mL and fTg/TSH ratio of ≥0.36 had the optimal sensitivity and specificity for detection of incomplete response 1 and 2 years after treatment. fTg<33.5 ng/mL had NPV of 98.5% for exclusion of distant metastases. Patients with fTg≥33.5 ng/mL had longer "time to excellent response" (3.6±2.3 vs. 2.0±1.8 yrs) and needed more additional treatments compared to patients with fTg<33.5 ng/mL. Multivariate analysis showed that fTg was the most potent risk factor for prediction of treatment failure 1 and 2 years after RIT. fTg of ≥33.5 ng/mL was the most important risk factor for prediction of treatment failure after RIT and could be included in decision algorithms regarding intensity of treatments in low/intermediate risk patients with DTC.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to define prognostic value and optimal threshold of first thyroglobulin (fTg) measured after thyroidectomy and just before radio-iodine therapy (RIT), in low/intermediate risk patients with differentiated thyroid cancer (DTC).
METHODS METHODS
This is a retrospective study in 383 patients with DTC who were treated with surgery followed by RIT. Response to treatment was assessed 1 and 2 years after RIT. Odds ratio of different risk factors like age, sex, TNM stage, fTg and Anti-Tg Ab were compared between patients with and without incomplete response 1 and 2 years after treatment. Receiver operating curve analysis was used for definition of optimal fTg cut off for detection of incomplete response.
RESULTS RESULTS
218 female and 55 male with DTC had negative anti-Tg antibody (mean age: 37.5±14.5 years) and analyzed separately. fTg≥33.5 ng/mL and fTg/TSH ratio of ≥0.36 had the optimal sensitivity and specificity for detection of incomplete response 1 and 2 years after treatment. fTg<33.5 ng/mL had NPV of 98.5% for exclusion of distant metastases. Patients with fTg≥33.5 ng/mL had longer "time to excellent response" (3.6±2.3 vs. 2.0±1.8 yrs) and needed more additional treatments compared to patients with fTg<33.5 ng/mL. Multivariate analysis showed that fTg was the most potent risk factor for prediction of treatment failure 1 and 2 years after RIT.
CONCLUSIONS CONCLUSIONS
fTg of ≥33.5 ng/mL was the most important risk factor for prediction of treatment failure after RIT and could be included in decision algorithms regarding intensity of treatments in low/intermediate risk patients with DTC.

Identifiants

pubmed: 30916533
pii: S1824-4785.19.03136-4
doi: 10.23736/S1824-4785.19.03136-4
doi:

Substances chimiques

Iodine Radioisotopes 0
Thyroglobulin 9010-34-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

64-71

Auteurs

S Rasoul Zakavi (SR)

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Narjess Ayati (N)

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Samira Zare (S)

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Abolfazl Ayati (A)

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Kayvan Sadri (K)

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Nazanin Fekri (N)

Department of Statistics, Mashhad University of Medical Sciences, Mashhad, Iran.

Bita Abbasi (B)

Department of Radiology, Mashhad University of Medical Sciences, Mashhad, Iran.

Susan Shafiei (S)

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran - susan.shafiei@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH